Roth Capital Trims PT on Ligand Pharma (LGND) to $150 Amid New Kyprolis Data (AMGN)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
The firm commented,
This is an unfortunate bump for Kyprolis. While Amgen has additional studies ongoing in the front-line setting, we believe that while product revenue will continue to grow, it could negatively impact the "slope" of the curve. Our adjusted revenue numbers for Kyprolis are below. With the negative data, Kyprolis remains in the negative perception zone for many, especially based on continuing commentary regarding the competitive landscape (Darzalex). We point to KOL feedback for the need of a proteasome inhibitor backbone and Kyprolis significantly outperformed Velcade in later treatment lines. Looking to our overall investment case for Ligand, we invoke our unchanged thesis of the company having a "buffered" downside based on negative partnered news based on 1) current core revenue streams, 2) new revenue streams just added and anticipated and 3) the sheer depth of the pipeline to spread overall risk out dramatically, in our belief.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Chipotle Mexican Grill (CMG) to Neutral; 'New Normal'
- Oppenheimer Raises Price Target on T-Mobile (TMUS) to $55 Following 3Q Report
- Jefferies Slashes PT, Estimates on Chipotle Mexican Grill (CMG)
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!